Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($2.16), $0.02 worse than the analyst estimate of ($2.14). Revenue for the quarter came in at $103.35 million versus the consensus estimate of $101.94 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.